One of the industry's most promising PACS companies is planningto go public. Cemax-Icon of Fremont, CA, is laying the groundworkfor issuing an initial public offering in the next several months.Company officials aren't saying much about the offering, in
One of the industry's most promising PACS companies is planningto go public. Cemax-Icon of Fremont, CA, is laying the groundworkfor issuing an initial public offering in the next several months.Company officials aren't saying much about the offering, in deferenceto the "quiet period" required by the Securities andExchange Commission before IPOs. They have confirmed that a prospectusfor the offering is being developed and should be available nextmonth.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.